نتائج البحث - "V A, Kozlov"

Relation: https://www.med-sovet.pro/jour/article/view/8392/7382; Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022. 239 с.; Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506–518. https://doi.org/10.21037/tlcr.2020.03.40.; Provencio M, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C et al. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl Lung Cancer Res. 2019;8(4):461–475. https://doi.org/10.21037/tlcr.2019.08.05.; Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68(6):551–564. https://doi.org/10.1136/thoraxjnl-2012-202297.; Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F et al. Stage III NonSmall-Cell Lung Cancer: An Overview of Treatment Options. Curr Oncol. 2023;30(3):3160–3175. https://doi.org/10.3390/curroncol30030239.; Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543.; Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937.; Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860–867. https://doi.org/10.1016/j.jtho.2020.12.015.; Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L et al. Fiveyear survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. J Clin Oncol. 2021;39(15):8511–8511. https://doi.org/10.1200/JCO.2021.39.15_suppl.8511.; Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023;18(2):181–193. https://doi.org/10.1016/j.jtho.2022.10.003.; Лактионов КК, Артамонова ЕВ, Борисова ТН, Бредер ВВ, Бычков ЮМ, Владимирова ЛЮ и др. Злокачественное новообразование бронхов и легкого: клинические рекомендации. М.; 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/30_3.; Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026.; Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG et al. Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR. J Thorac Oncol. 2023;18(8):1042–1054. https://doi.org/10.1016/j.jtho.2023.04.008.; Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N et al. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J Radiat Res. 2023;64(1):142–153. https://doi.org/10.1093/jrr/rrac057.; Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 2020;150:114–122. https://doi.org/10.1016/j.lungcan.2020.10.006.; Park JE, Hong KS, Choi SH, Lee SY, Shin KC, Jang JG et al. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. Clin Lung Cancer. 2024;25(4):354–364. https://doi.org/10.1016/j.cllc.2024.02.006.; Waterhouse D, Yong C, Frankart A, Brannman L, Mulrooney T, Robert N et al. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting. Future Oncol. 2023;19(28):1905–1916. https://doi.org/10.2217/fon-2023-0117.; Vrankar M, Stanic K, Jelercic S, Ciric E, Vodusek AL, But-Hadzic J. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience. Radiol Oncol. 2021;55(4):482–490. https://doi.org/10.2478/raon-2021-0044.; Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E et al. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front Oncol. 2021;11:744956. https://doi.org/10.3389/fonc.2021.744956.; Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M et al. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clin Transl Oncol. 2024;26(7):1779–1789. https://doi.org/10.1007/s12094-024-03404-9.; Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N et al., Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022;17(12):1415–1427. https://doi.org/10.1016/j.jtho.2022.07.1148.; Zhao B, Li H, Wu J, Ma W. Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2023;18(1):1–2. https://doi.org/10.1016/j.jtho.2022.09.002.; https://www.med-sovet.pro/jour/article/view/8392